GSE62254 | GSE29272 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 | Immunity L | Immunity M | Immunity H |  | Immunity L | Immunity M | Immunity H | ||||||
 | No. | % | No. | % | No. | % |  | No. | % | No. | % | No. | % |
Age | Age | ||||||||||||
< 60 | 10 | 9.4% | 79 | 74.5% | 17 | 16.0% | < 60 | 11 | 16.4% | 41 | 61.2% | 15 | 22.4% |
≥60 | 22 | 11.6% | 140 | 74.1% | 27 | 14.3% | ≥60 | 7 | 11.9% | 48 | 81.4% | 4 | 6.8% |
Gender | Gender | ||||||||||||
Male | 24 | 12.3% | 143 | 73.3% | 28 | 14.4% | Male | 14 | 14.1% | 70 | 70.7% | 15 | 15.2% |
Female | 8 | 8.0% | 76 | 76.0% | 16 | 16.0% | Female | 4 | 14.8% | 19 | 70.4% | 4 | 14.8% |
pStage | pStage | ||||||||||||
I/II | 14 | 11.3% | 93 | 75.0% | 17 | 13.7% | I/II | 2 | 20.0% | 8 | 80.0% | 0 | 0.0% |
III/IV | 18 | 10.5% | 126 | 73.7% | 27 | 15.8% | III/IV | 16 | 13.8% | 81 | 69.8% | 19 | 16.4% |
Metastasis | |||||||||||||
 Yes | 16 | 11.3% | 110 | 77.5% | 16 | 11.3% |  |  |  |  |  |  |  |
 No | 16 | 10.5% | 109 | 71.2% | 28 | 18.3% |  |  |  |  |  |  |  |